Access Systems awarded $3.5M contract to aid HHS FTS2001-Networx Transition Program Management Office Access Systems, Inc. , an information technology solutions provider, has been awarded a $3 drug information .5M contract by GSA’s National Capital Region to support the Section of Health insurance and Human Solutions FTS2001-Networx Transition Program Management Workplace. Our team’s domain knowledge and experience provides us insight into the current environment of how procedures and technologies can be leveraged to better support the Division of Health and Human Services’ critical mission in the future, stated Julie S.
Revimmune carries a risk management system to enhance patient protection by ensuring appropriate patient selection, supportive treatment, and tracking of outcomes data. The main investigator for the Phase 2 study with Revimmune at Johns Hopkins University College of Medicine is Dr. Douglas Kerr, associate professor of neurology. The co-principal investigators on this study are Dr. Daniel Drachman, Dr. Robert Brodsky, and Dr. Adam Kaplin. The National Multiple Sclerosis Culture has supported the medical process at Johns Hopkins University.. Accentia announces investigational new drug application for Revimmune for refractory MS Accentia Biopharmaceuticals has announced that it met with the Food and Drug Administration on September 26, 2007 for a scheduled pre-Investigational New Medication meeting on Revimmune.